A. M. Mulligan, Javier Godino 19 , Maroulio Pertesi 20 Caroline Seynaeve 38 , Madeleine MA Tilanus-Linthorst 39 , Rob B van der Luijt 40, Theo van Os 41 , Matti Rookus 32 , Debra Frost 3 , J Louise Jones 42 , D Gareth Evans 43 , Fiona Lalloo 43 , Ros Eeles 44 , Louise Izatt 45 , Julian Adlard 46 , Rosemarie Davidson 47 , Jackie Cook 48 We thank the NEYE Foundation for financial support The Deutsches Krebsforschungszentrum (DKFZ) study The study was supported by the DKFZ

M. Barile-of-the-istituto-europeo-di-oncologia, I. Milan, L. Kai-ren-ong, J. H. , J. Paterson et al., South West Regional Genetics Service South East of Scotland Regional Genetics Service, Edinburgh: Mary Porteous, Sarah Drummond. Peninsula Clinical Genetics Service West of Scotland Regional Genetics Service South East Thames Regional Genetics Service, Guy's Hospital London The Institute of Cancer Research and Royal Marsden NHS Foundation Trust The Investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Istituto Nazionale per la Ricerca sul Cancro Epidemiological study of BRCA1 and BRCA2 mutation carriers (EMBRACE) EMBRACE Collaborating Centers are: Coordinating Centre: Rebecca Collier. Northern Clinical Genetics Service EMBRACE is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990. D. Gareth Evans and Fiona Lalloo are supported by an NIHR grant to the Biomedical Research Centre and Lucia D'Mello are also supported by Cancer Research UK Grant C5047/A8385. Fox Chase Cancer Center Study (FCCC) Fox Chase Cancer Center Biosample Repository: We acknowledge M. Pat Gilroy Donovan, and Meghan Butler for their help collecting patient data and samples

A. K. Was, U. By, and 5. The-eileen-stein-jacoby-fund, The author acknowledges support from The University of Kansas Cancer Center and the Kansas Bioscience Authority Eminent Scholar Program. A.K.G. is the Chancellors Distinguished Chair in Biomedical Sciences endowed Professor. Georgetown University Work is supported by the Familial Cancer Registry (CI) and the Tissue Culture Shared Registry at Georgetown University, NIH/NCI grant P30-CA051008), the Cancer Genetics Network (HHSN261200744000C) (CI), and Swing Fore the Cure (CI)

C. Paul-strauss-emmanuelle-barouk-simonet, F. Bonnet, V. B. Henry, T. Lynch, C. L. Snyder et al., Nice: Marc Frénay. CHU de Limoges: Laurence Vénat-Bouvet. CHU de Nantes: Capucine Delnatte The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) HEBON Collaborating Centers: Coordinating center: Netherlands Cancer Institute The Netherlands Foundation for the detection of hereditary tumours, MJ

F. Helsinki, L. Street, and . Angeles, CA 90089-9237, USA. 8 Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, 10065, USA. 9 National Cancer Institute, Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch, p.6120, 2001.

E. Blvd and . Rockville, 11 Centre of Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology Université Lyon 1, Cancer Research Center of Lyon, 28 rue Laënnec 14 Department of Molecular and Regenerative Medicine Hospital clinico Universitario, 10 Queensland Institute of Medical Research, 300 Herston Rd Germany. 12 Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Centre Hospitalier Universitaire de Lyon/Centre Léon Bérard, 28 rue Laënnec, Lyon 69373, France. 13 INSERM U1052, CNRS UMR5286 Santariskiu st 2, LT-08661 Vilnius and State Research Institute Innovative Medicine Center, Zygimantu st. 9, LT-01102 Vilnius, Lithuania. 15 Center for Genomic Medicine DK-2100 Copenhagen, Denmark. 17 Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre, C/Melchor Fernández Almagro 3 and the Spanish Network on Rare Diseases (CIBERER). 18 Institute of Biology and Molecular Genetics C/Sanz y Forés Instituto de investigación sanitaria de Aragón (IIS), p.20

I. , N. Center-for-scientific-research-demokritos, P. Gregoriou, E. Str, A. Milan et al., Spain and the Spanish Network on Rare Diseases (CIBERER) 22 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumouri (INT), via Giacomo Venezian 1 via Giacomo Venezian 1, Milan, 20133, Italy. 24 Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia, via Ripamonti 435 25 Unit of Experimental Oncology 1, Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy. 26 Department of Genetics 27 Medical Genetics Unit, Department of Clinical Physiopathology 28 Department of Molecular Medicine 29 Division of Medical Oncology 32 Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands. 33 Department of Clinical Genetics, VU Medical Center, Amsterdam, The Netherlands The Netherlands. 35 Department of Clinical Genetics and GROW, School for Oncology and Developmental Biology, MUMC, Maastricht, The Netherlands. 36 Department of The Netherlands. 37 Department of, 21 Human Genetics Group and Genotyping Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre 31 Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ) The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, UK. 45 Clinical Genetics, Guy's and St. Thomas' NHS Foundation Trust, 15310.

Y. Regional, G. Service, U. Leeds, . Ferguson-smith, . Centre et al., 51 North of Scotland Regional Genetics Service, NHS Grampian and University of Aberdeen, Foresterhill, Aberdeen, UK. 52 Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, UK. 53 Cheshire and Merseyside Clinical Genetics Service, Liverpool Women's NHS Foundation Trust, Liverpool, UK. 54 Leicestershire Clinical Genetics Service, 56 All Wales Medical Genetics Service. 57 All Wales Medical Genetics Services. 59 Institute for Medical Informatics, pp.61-63

C. Berlin and G. , 70 Centre of Familial Breast and Ovarian Cancer, Department of Medical Genetics, Institute of Human Genetics, University Würzburg, Germany. 71 Institute of Human Genetics, University Regensburg, Germany. 72 Institute of Human Genetics, University Leipzig, Germany. 73 Institute of Human Genetics, University Hospital, Frankfurt a.M., Germany. 74 Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, UK. 75 Service de Génétique Oncologique, Institut Curie Genetic Unit, Avicenne Hospital Hospital Clinico, vol.79, issue.87, p.86

I. Hereditary-cancer-program, H. Català-d-'oncologia, Q. Duran-i-reynals-bellvitge-biomedical-research-institute, and C. , Canada Research Chair in Oncogenetics 91 Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV -IRCCS, Via Gattamelata 64, 35128 Padua, Italy. 92 Department of Oncology and Surgical Sciences, University of Padua and Istituto Oncologico Veneto IOV -IRCCS, Via Gattamelata 64 94 Department of Anatomical Pathology, Prince of Wales Hospital 95 Abramson Cancer Center and University of Pennsylvania Perelman School of Medicine 97 City of Hope Comprehensive Cancer Center and Department of Population Sciences, Beckman Research Institute, City of Hope, 98 Departments of Medicine, and Preventive Medicine and Public Health. 99 Jonsson Comprehensive Cancer Center at the University of California. 101 Department of Health Sciences Research, pp.3-57

C. On, 110 Cancer Care Ontario, ON, Canada. 111 Departments of Molecular Virology The Ohio State University Comprehensive Cancer Center 113 Clinical Genetics 114 Department of Clinical Genetics 116 Section of Genetic Oncology 120 Division of Clinical Genetics 122 Department of Population Sciences, the Beckman Research Institute of the City of Hope, 123 UCSF Cancer Risk Program and Departments of Medicine and Epidemiology and Biostatistics. 125 Department of Cancer Prevention and Control. 126 Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center. 128 Fox Chase Cancer Center, pp.127-110, 2011.

P. Philadelphia, U. Melbourne, . Vic, and . Australia, 131 Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Samuel Lunenfeld Research Institute, p.135

C. On, 136 Breast Cancer Family Registry. 137 Cancer Genetics Network " Groupe Génétique et Cancer, Fédération Nationale des Centres de Lutte Contre le Cancer

D. Ford, D. Easton, D. Bishop, S. Narod, and D. Goldgar, Risks of cancer in BRCA1-mutation carriers, The Lancet, vol.343, issue.8899, pp.692-695, 1994.
DOI : 10.1016/S0140-6736(94)91578-4

D. Thompson and D. Easton, Cancer Incidence in BRCA1 Mutation Carriers, CancerSpectrum Knowledge Environment, vol.94, issue.18, pp.1358-1365, 2002.
DOI : 10.1093/jnci/94.18.1358

N. Mavaddat, P. Pharoah, F. Blows, K. Driver, E. Provenzano et al., Familial relative risks for breast cancer by pathological subtype: a population-based cohort study, Breast Cancer Research, vol.101, issue.Suppl 2, p.10, 2010.
DOI : 10.1093/jnci/djp167

D. Thompson and D. Easton, The Genetic Epidemiology of Breast Cancer Genes, Journal of Mammary Gland Biology and Neoplasia, vol.9, issue.3, pp.221-236, 2004.
DOI : 10.1023/B:JOMG.0000048770.90334.3b

A. Antoniou, P. Pharoah, S. Narod, H. Risch, J. Eyfjord et al., Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies, The American Journal of Human Genetics, vol.72, issue.5, pp.1117-1130, 2003.
DOI : 10.1086/375033

C. Begg, R. Haile, A. Borg, K. Malone, P. Concannon et al., Variation of Breast Cancer Risk Among BRCA1/2 Carriers, JAMA, vol.299, issue.2, pp.194-201, 2008.
DOI : 10.1001/jama.2007.55-a

D. Ford, D. Easton, M. Stratton, S. Narod, D. Goldgar et al., Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families, The American Journal of Human Genetics, vol.62, issue.3, pp.676-689, 1998.
DOI : 10.1086/301749

J. Hopper, M. Southey, G. Dite, D. Jolley, G. Giles et al., Population-based estimate of the average agespecific cumulative risk of breast cancer for a defined set of proteintruncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study, Cancer Epidemiol Biomarkers Prev, vol.8, pp.741-747, 1999.

R. Milne, A. Osorio, T. Cajal, A. Vega, G. Llort et al., The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain, Clinical Cancer Research, vol.14, issue.9, pp.2861-2869, 2008.
DOI : 10.1158/1078-0432.CCR-07-4436

S. Simchoni, E. Friedman, B. Kaufman, R. Gershoni-baruch, A. Orr-urtreger et al., Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population, Proceedings of the National Academy of Sciences, vol.103, issue.10, pp.3770-3774, 2006.
DOI : 10.1073/pnas.0511301103

J. Struewing, P. Hartge, S. Wacholder, S. Baker, M. Berlin et al., among Ashkenazi Jews, New England Journal of Medicine, vol.336, issue.20, pp.1401-1408, 1997.
DOI : 10.1056/NEJM199705153362001

T. Sorlie, R. Tibshirani, J. Parker, T. Hastie, J. Marron et al., Repeated observation of breast tumor subtypes in independent gene expression data sets, Proceedings of the National Academy of Sciences, vol.100, issue.14, pp.8418-8423, 2003.
DOI : 10.1073/pnas.0932692100

. Van-'t, L. Veer, H. Dai, M. Van-de-vijver, Y. He et al., Gene expression profiling predicts clinical outcome of breast cancer, Nature, vol.415, pp.530-536, 2002.

S. Lakhani, J. Jacquemier, J. Sloane, B. Gusterson, T. Anderson et al., Multifactorial Analysis of Differences Between Sporadic Breast Cancers and Cancers Involving BRCA1 and BRCA2 Mutations, JNCI Journal of the National Cancer Institute, vol.90, issue.15, pp.1138-1145, 1998.
DOI : 10.1093/jnci/90.15.1138

S. Lakhani, J. Reis-filho, L. Fulford, F. Penault-llorca, M. Van-der-vijver et al., Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype, Clinical Cancer Research, vol.11, issue.14, pp.5175-5180, 2005.
DOI : 10.1158/1078-0432.CCR-04-2424

A. Bane, J. Beck, I. Bleiweiss, S. Buys, E. Catalano et al., BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays, The American Journal of Surgical Pathology, vol.31, issue.1, pp.2121-128, 2007.
DOI : 10.1097/01.pas.0000213351.49767.0f

S. Ahmed, G. Thomas, M. Ghoussaini, C. Healey, M. Humphreys et al., Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2, al: Newly discovered breast cancer susceptibility loci on 3p24 and 17q23, pp.585-590, 2009.
DOI : 10.1038/ng2142

C. Haiman, L. Kolonel, B. Henderson, L. Marchand, L. Brennan et al., Genome-wide association study identifies novel breast cancer susceptibility loci, Nature, vol.447, pp.1087-1093, 2007.

D. Hunter, P. Kraft, K. Jacobs, D. Cox, M. Yeager et al., A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer, Nature Genetics, vol.164, issue.7, pp.870-874, 2007.
DOI : 10.1371/journal.pgen.0020190

S. Stacey, A. Manolescu, P. Sulem, T. Rafnar, J. Gudmundsson et al., Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor???positive breast cancer, Nature Genetics, vol.59, issue.7, pp.865-869, 2007.
DOI : 10.1038/ng1732

S. Stacey, A. Manolescu, P. Sulem, S. Thorlacius, S. Gudjonsson et al., Common variants on chromosome 5p12 confer susceptibility to estrogen receptor???positive breast cancer, Nature Genetics, vol.40, issue.6, pp.703-706, 2008.
DOI : 10.1158/1078-0432.CCR-05-1530

G. Thomas, K. Jacobs, P. Kraft, M. Yeager, S. Wacholder et al., A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24, Nat Genet, vol.1, issue.41, pp.579-584, 2009.

C. Turnbull, S. Ahmed, J. Morrison, D. Pernet, A. Renwick et al., Genome-wide association study identifies five new breast cancer susceptibility loci, Nature Genetics, vol.447, issue.6, pp.504-507, 2010.
DOI : 10.1093/bioinformatics/btm108

S. Zeger, K. Liang, and P. Albert, Models for Longitudinal Data: A Generalized Estimating Equation Approach, Biometrics, vol.44, issue.4, pp.1049-1060, 1988.
DOI : 10.2307/2531734

A. Broeks, M. Schmidt, M. Sherman, F. Couch, J. Hopper et al., Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium, Human Molecular Genetics, vol.20, issue.16, pp.3289-3303, 2011.
DOI : 10.1093/hmg/ddr228

M. Garcia-closas, P. Hall, H. Nevanlinna, K. Pooley, J. Morrison et al., Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics, PLoS Genetics, vol.4, issue.4, p.1000054, 2008.
DOI : 10.1371/journal.pgen.1000054.s016

A. Antoniou, C. Kartsonaki, O. Sinilnikova, P. Soucy, L. Mcguffog et al., Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers, Human Molecular Genetics, vol.20, issue.16, pp.3304-3321, 2011.
DOI : 10.1093/hmg/ddr226
URL : https://hal.archives-ouvertes.fr/hal-00771696

A. Antoniou, A. Spurdle, O. Sinilnikova, S. Healey, K. Pooley et al., Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers, The American Journal of Human Genetics, vol.82, issue.4, pp.937-948, 2008.
DOI : 10.1016/j.ajhg.2008.02.008

A. Antoniou, O. Sinilnikova, L. Mcguffog, S. Healey, H. Nevanlinna et al., Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers, Human Molecular Genetics, vol.18, issue.22, pp.4442-4456, 2009.
DOI : 10.1093/hmg/ddp372

A. Antoniou, J. Beesley, L. Mcguffog, O. Sinilnikova, S. Healey et al., Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction, Cancer Research, vol.70, issue.23, pp.9742-9754, 2010.
DOI : 10.1158/0008-5472.CAN-10-1907

G. Reeves, R. Travis, J. Green, D. Bull, S. Tipper et al., Incidence of Breast Cancer and Its Subtypes in Relation to Individual and Multiple Low-Penetrance Genetic Susceptibility Loci, JAMA, vol.304, issue.4, pp.426-434, 2010.
DOI : 10.1001/jama.2010.1042

G. Chenevix-trench, R. Milne, A. Antoniou, F. Couch, D. Easton et al., An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA), Breast Cancer Res, vol.9, issue.34, 2007.

A. Antoniou, D. Goldgar, N. Andrieu, J. Chang-claude, R. Brohet et al., A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes, Genetic Epidemiology, vol.10, issue.1, pp.1-11, 2005.
DOI : 10.1002/gepi.20074

A. Antoniou, O. Sinilnikova, J. Simard, M. Leone, M. Dumont et al., Genetic Modifiers of Cancer Risk in BRCA1/2 Mutation Carriers Study (GEMO), C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies, pp.51-135

A. Antoniou, P. Pharoah, G. Mcmullan, N. Day, B. Ponder et al., Evidence for further breast cancer susceptibility genes in addition toBRCA1 andBRCA2 in a population-based study, Genetic Epidemiology, vol.265, issue.1, pp.1-18, 2001.
DOI : 10.1002/gepi.1014

N. Mavaddat, T. Rebbeck, S. Lakhani, D. Easton, and A. Antoniou, Incorporating tumour pathology information into breast cancer risk prediction algorithms, Breast Cancer Research, vol.21, issue.Suppl 2, p.28, 2010.
DOI : 10.1002/gepi.1014

K. Lange, D. Weeks, M. Boehnke, . Mendel, and . Fisher, Programs for pedigree analysis: Mendel, Fisher, and dGene, Genetic Epidemiology, vol.5, issue.6, pp.471-472, 1988.
DOI : 10.1002/gepi.1370050611

A. Antoniou, A. Cunningham, J. Peto, D. Evans, F. Lalloo et al., The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions, British Journal of Cancer, vol.98, issue.8, pp.1457-1466, 2008.
DOI : 10.1136/jmg.2004.028829

D. Boos, On generalised score tests, American Statistician, vol.46, pp.327-333, 1992.

S. Stacey, P. Sulem, C. Zanon, S. Gudjonsson, G. Thorleifsson et al., Ancestry-Shift Refinement Mapping of the C6orf97-ESR1 Breast Cancer Susceptibility Locus, PLoS Genetics, vol.304, issue.7, p.1001029, 2010.
DOI : 10.1371/journal.pgen.1001029.s014

W. Zheng, J. Long, Y. Gao, C. Li, Y. Zheng et al., Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1, Nature Genetics, vol.63, issue.3, pp.324-328, 2009.
DOI : 10.1002/gepi.20098

A. Antoniou, X. Wang, Z. Fredericksen, L. Mcguffog, R. Tarrell et al., A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor???negative breast cancer in the general population, Nature Genetics, vol.447, issue.10, pp.885-892, 2010.
DOI : 10.1002/gepi.1370050611
URL : https://hal.archives-ouvertes.fr/hal-00698376

R. Milne, J. Benitez, H. Nevanlinna, T. Heikkinen, K. Aittomaki et al., Risk of Estrogen Receptor-Positive and -Negative Breast Cancer and Single-Nucleotide Polymorphism 2q35-rs13387042, JNCI Journal of the National Cancer Institute, vol.101, issue.14, pp.1012-1018, 2009.
DOI : 10.1093/jnci/djp167

N. Mavaddat, A. Antoniou, D. Easton, and M. Garcia-closas, Genetic susceptibility to breast cancer, Molecular Oncology, vol.41, issue.3, pp.174-191, 2010.
DOI : 10.1016/j.molonc.2010.04.011

S. Wacholder, S. Han, and C. Weinberg, Inference From a Multiplicative Model of Joint Genetic Effects for Ovarian Cancer Risk, JNCI Journal of the National Cancer Institute, vol.103, issue.2, pp.82-83, 2011.
DOI : 10.1093/jnci/djq510

M. Hammond, D. Hayes, M. Dowsett, D. Allred, K. Hagerty et al., College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version), Arch Pathol Lab Med, vol.134, pp.48-72, 2010.

L. Collins, M. Botero, and S. Schnitt, Bimodal Frequency Distribution of Estrogen Receptor Immunohistochemical Staining Results in Breast Cancer, American Journal of Clinical Pathology, vol.123, issue.1, pp.16-20, 2005.
DOI : 10.1309/HCF035N9WK40ETJ0

R. Milne and A. Antoniou, Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers, Annals of Oncology, vol.22, issue.suppl 1, pp.11-17, 2011.
DOI : 10.1093/annonc/mdq660

O. Fletcher, N. Johnson, N. Orr, F. Hosking, L. Gibson et al., Novel Breast Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association Study, JNCI Journal of the National Cancer Institute, vol.103, issue.5, pp.425-435, 2011.
DOI : 10.1093/jnci/djq563

M. Gaudet, T. Kirchhoff, T. Green, J. Vijai, J. Korn et al., Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer, PLoS Genetics, vol.6, issue.10, p.1001183, 2010.
DOI : 10.1371/journal.pgen.1001183.s008

. Mulligan, Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1, Breast Cancer Research, vol.13, issue.2, pp.10-1186, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-00670601